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The objective of this study was to evaluate the prognostic value of ARID1A, p53, p21, p16
and ß-Catenin in endometrioid and clear cell ovarian and endometrial carcinomas.
Materials and methods
97 tumors were available for analysis of ARID1A, p53, p21, p16 and ß-Catenin with the tech-
niques of tissue microarray and immunohistochemistry. 32 were ovarian carcinomas and 65
were endometrial carcinomas.
Results
Endometrioid ovarian carcinomas showed negative staining for ARID1A (a) and p21 (b),
aberrant expression of p53 (c) and p16 (d) and ß-Catenin positive nuclear expression (e)
respectively in 19% (a), 100% (b), 28.6% (c), 52.4% (d) and 4.8% (e) of all cases. In the
group of clear cell ovarian carcinomas it was 63.6% (a), 100% (b), 81.8% (c), 54.5% (d) and
0% (e). For endometrioid uterine carcinomas it was 75.7% (a), 94.9% (b), 30.5% (c), 52.1%
(d) and 6.8% (e) and for clear cell uterine carcinomas it was 8.6% (a), 100% (b), 50% (c),
100% (d) and 0% (e). Survival analysis showed that negative expression of ARID1A, p53
aberrant expression and ß-Catenin nuclear positive staining are independent negative prog-
nosticators in both, clear cell and endometrioid carcinoma, regardless of ovarian or uterine
origin. Cox-Regression analysis showed them again as negative prognostic factors. Further-
more, we found a significant correlation between ARID1A and ß-Catenin expression in
endometrioid uterine tumors.
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Conclusion
The analyzed gynaecological carcinoma showed a distinct expression scheme of proteins
that are associated with tumor suppression. We may conclude that ARID1A, p53 and ß-
Catenin are the strongest prognostic factors by analyzing a subgroup of tumor suppressor
genes in clear cell and endometrioid subtypes of ovarian and endometrial cancer and may
be used along with traditional morphological and clinical characteristics for prognosis.
Introduction
The traditional histopathological classification of endometrial epithelial cancer, which was first
proposed by Bokhman, includes type I tumors that are usually estrogen-dependent low-grade
endometrioid cancers and type II tumors which are usually estrogen-independent high-grade
serous or clear cell carcinomas [1]. While the first pathogenetic type has a frequency of 80–
90% and is associated with highly or moderately differentiated tumors with a favorable prog-
nosis, the second type has a frequency of only 10–20% and includes poorly differentiated
tumors with a doubtful prognosis [1].
For ovarian epithelial cancer pathogenesis a less accepted paradigm exists suggesting to dif-
fer between type I and type II molecular profiles [2]. Type I tumors contain endometrioid,
clear cell and low-grade serous carcinoma and mostly arise from atypical endometriosis or
from borderline serous tumors [2,3]. Type II carcinomas include high-grade serous, which
show typically a p53 mutation and, at least for patients with a BRCA mutation frequently arise
from the fimbriated end of the fallopian tube via serous tubar intraepithelial carcinoma (STIC)
[4,5].
Many studies have aimed to understand the cell origin and pathogenesis of these cancer
subtypes in order to better diagnose and treat patients. Recently several studies suggested that
the origin of clear cell and endometrioid carcinomas might derive from atypical endometri-
osis, which is believed to originate from the endometrium by retrograde menstruation [6–8].
The three-staged tumor grading system of endometrioid ovarian carcinoma is equivalent to
the grading of endometrioid endometrial cancer and considers growth patterns and nuclear
aplasia while there is no validated grading system for clear cell ovarian cancer, which are still
classified as high-grade carcinoma [9].
Considerable interest has not only been generated in understanding the pathogenesis but
also in the identification of factors that influence the prognosis of these tumors. Early diagnosis
of epithelial ovarian and uterine cancer is critical for patient survival. Ovarian cancer has the
highest mortality rate of the three main malignant tumors of the female reproductive system,
with an overall 5-year survival rate of 45% [10]. Known prognostic factors of ovarian and
endometrial carcinoma are histological subtype, tumor grading, International Federation of
Gynecology and Obstetrics (FIGO) staging as well as estrogen receptor positivity for endome-
trial carcinoma and age, general condition and residual tumor for ovarian cancer [9,11]. Previ-
ous studies have explored molecular alterations in clear cell and endometrioid ovarian and
endometrial tumors as additional prognostic factors, including changes in expression of
ARID1A, p53, p21, p16 and ß-Catenin carcinoma.
ARID1A is a recently identified tumor suppressor participating in forming SWI/SNF chro-
matin complexes [12]. Somatic inactivating mutations of ARID1A and loss of ARID1A expres-
sion appear to be an early event in the development of most ovarian clear cell and
endometrioid carcinomas as well as atypical endometriosis [13,14]. ARID1A is also frequently
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mutated and plays an important role in tumor progression in uterine endometrioid carcinoma
[15,16].
p53 is a well-studied tumor suppressor gene that plays a key role in regulating the cell cycle.
It is a principal mediator of growth arrest, senescence and apoptosis in response to a broad
array of cellular damage [17]. The p53 wild-type protein directly induces the expression of the
p21 protein which binds to a variety of cyclin-dependent kinases and inhibits their activity as
well as regulates the repair of DNA and blocks its replication by inhibiting cell-cycle progres-
sion [18,19].
The p16 protein is also a tumor suppressor gene that, in response to various stresses, inhib-
its cyclin-dependent kinases and causes the arrest of the cell-cycle in G1 phase [20].
ß-Catenin however is the effector of the Wnt signaling pathway [21]. It accumulates in cell-
cell junctions in cells not receiving the Wnt signal bound by a complex referred to as the
destruction complex. When cells receive the Wnt signal it is stabilized, enters the nucleus and
activates Wnt target genes [21]. Inappropriate activation of the Wnt pathway underlies many
cancers including ovarian and uterine carcinoma, mostly endometrioid [22].
In this study the expression of ARID1A, p53, p21, p16 and ß-Catenin was determined in 97
tumors by performing immunohistochemistry to evaluate their prognostic value. Human tissue
samples of the ovary and the uterus, obtained after surgical resection, were used to investigate
the correlation between their expression and clinical parameters, including overall survival.
Materials and methods
Tumors and patients
This study assessed 97 patients who all underwent primary surgery between January 1, 1990
and December 31, 2001 in the Department of Gynaecology, Ludwig-Maximilians-University,
Munich, Germany. A total of 59 cases were endometrioid uterine carcinoma, 6 clear cell uter-
ine carcinoma, 21 endometrioid ovarian carcinoma and 11 clear cell ovarian carcinoma. The
analyzed tissue samples were taken from the hospital archive of the Department of Pathology,
Ludwig-Maximilians-University, Munich, Germany. In cooperation with the tumor register of
Munich necessary data about the patients’ survival was available. The patients were staged and
the tumors graded according to 1988 International Federation of Gynaecology and Obstetrics
(FIGO) criteria [23]. Patients’ characteristics, e.g. age, FIGO stage, histological subtype and
FIGO grade are shown in Table 1. Survival was taken from the date of confirmed histological
diagnosis after primary surgery to the date of recurrence or last visit.
Ethical approval
All patients´ data were fully anonymized, and the study was performed according to the stan-
dards set in the Declaration of Helsinki 1975. All tumor tissue used was leftover material that
had initially been collected for histopathological diagnostics. All diagnostic procedures had
already been fully completed when samples were retrieved for the study. The current study
was approved in writing by the Ethics Committee of the Ludwig Maximilians University,
Munich, Germany (approval number 449–14). Authors were blinded for clinical information
during experimental analysis.
Sampling and tissue microarray construction of ovarian and uterine cancer
tissue
New samples from the original slides of tumors were taken and representative areas of tumor
tissues were selected. Three core biopsies from each specimen were removed and attached on
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tissue microarrays. The presence of tumor tissue on the arrayed samples was verified by a
pathologist.
Immunohistochemistry and interpretation
Serial sections of the recipient tissue microarray paraffin blocks were cut at 2–3 μm, deparaffi-
nized with xylene, and rehydrated through a series of graded alcohols. The immunostaining
procedure was performed using an automated stainer (Benchmark1 XT, Ventana). The fol-
lowing monoclonal primary antibodies were used: ARID1A/BAF250a Rabbit mAb (New
England Biolabs GmbH) directed against ARID1A protein, p53 Ab-5 (Thermo Scientific)
directed against 53, p16-Arc (p16INK4a, CINtec1 Histology) directed against p16, p21 Cip
(CDKN1A) directed against p21 and ß-Catenin Mouse IgG-1 (Roche, Ventana, ready to use)
directed against ß-Catenin. All staining’s were performed at the Department of Pathology,
Ludwig-Maximilians-University, Munich.
The IHC stains were evaluated by the authors (MH and DM) in a double-blind process
using the immunoreactive Remmele score (IRS) [24]. The quantity of cells stained was scored
as: 0 = no staining, 1 = 1–10%, 2 = 11–50%, 3 = 51–80% and 4 =>81% staining. The IRS was
rendered as a product of the scores obtained for staining intensity (0 = no expression, 1 =
weak expression, 2 = moderate expression, 3 = strong expression) and quantity. A total score
of 0–2 was considered negative, 3–5: weak, 6–8: moderate and 9–12: strong immunoreactivity.
ARID1A and p21 were dichotomized into negative (0–2 points in IRS) and positive cases
(3–12 points in IRS) and p53 and p16 were dichotomized into no expression/overexpression
(= aberrant) and normal expression (= regulated). Weak to moderate immunoreactivity (3–8
points in IRS) was considered p53/p16 normal expression. Strong and diffuse nuclear p53/p16
immunoexpression (9–12 points in IRS) or complete absence of p53/p16 staining (0–2 points
in IRS) was interpreted as likely indicating a p53/p16 gene mutation. The presence of rare
weakly positive nuclear staining is a pattern that is commonly associated with wild type p53
and can be found in normal ovarian and uterine tissues [25]. ß-Catenin was classified in 3
groups of ß-Catenin nuclear negative (0–2 points in IRS) and membrane positive (n-m+)
staining (3–12 points in IRS), nuclear negative (0–2 points in IRS) and membrane weak (3–6
points in IRS) or negative staining (n-m-) (0–2 points in IRS) and ß-Catenin nuclear and
membrane/cytoplasm positive (n+m+) staining (3–12 points in IRS) (Fig 1).
Table 1. Patients characteristics (N = 97).
Age (median) 61.0 (range 35–82)
Histopathology
Clear cell uterine carcinoma 6 (6.2)
Endometrioid uterine carcinoma 59 (60.8)
Clear cell ovarian carcinoma 11 (11.3)
Endometrioid ovarian carcinoma 21 (21.6)
Tumor grading
Grade 1 27 (27.8)
Grade 2 29 (29.9)
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Statistical analysis
For statistical analysis the SPSS Statistics Version 23 (SPSS Inc., Chicago, IL, USA) was used.
For testing proportional differences in univariate analysis the Pearson’s Chi-square test or
Fisher’s exact test for qualitative variables and unpaired t-test for quantitative normally distrib-
uted variables was applied. For normally distributed variables in several groups the single-fac-
tor variance analysis was used. The survival curves were generated by using the Kaplan Meier
technique and differences between these curves were tested by the log-rank test. All tests were
two-sided and the level of statistical significance was accepted at p 0.05. For multivariate
analyses the Cox regression model was used with tumor-related death as the endpoint.
Results
Results from immunohistochemistry
ARID1A. ARID1A nuclear positive staining was observed in 27 (27.8) out of 97 tumors.
The ARID1A status was significantly (p< 0.001) related to histological subtype (Table 2). Posi-
tive nuclear staining seen more frequently in endometrioid tumors and it was infrequent in
clear cell carcinoma. The ARID1A status alone was not associated with tumor grade (p =
0.581) or age (p = 0.369), but it was related statistically significantly to FIGO stage (p< 0.001).
Positive nuclear staining for ARID1A was seen more frequently in FIGO I tumors while FIGO
III and IV tumors were mostly ARID1A negative (S1 Fig). Survival analysis (Fig 2) demon-
strated significant (p = 0.014) differences for patients according to the ARID1A status. Patients
with ARID1A negative tumors had a 5-year survival of 60.2% compared with 84.9% survival
for those with ARID1A positive tumors. Significantly better survival in the subgroup of
ARID1A positive tumors could also be observed for sole analysis of all endometrioid (p =
0.039) and all ovarian carcinoma (p = 0.008) as well as tumors of grading G3 (p = 0.028).
Fig 1. Immunohistochemical stainings for ß-Catenin, p53, ARID1A, p16 and p21 in clear-cell (A and B) and endometrioid (C—K) carcinomas.
Focal, very weak membranous (n-m-) (A), membranous (n-m+) (B) and nuclear (n+m+) (C) expression of β-catenin. Regulated (D) and aberrant (E)
expression of p53. Preserved expression of ARID1A (F) and loss (G) of ARID1A expression. Negative staining (H) and positive (I) staining for p16.
Negative (J) and positive staining (K) of p21. 400 × magnification was used for all pictures; scale bar (K) refers to 60 μm for all images.
https://doi.org/10.1371/journal.pone.0192881.g001
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Table 2. Status of ARID1A, p53, p21, p16 and ß-Catenin according to histological subtypes (N = 97).














64 (66.0) 28 (28.9) 5 (5.2)
Histology
Clear cell uterine 6 (8.6) 0 (0) 3 (8.3) 3 (4.9) 6 (12.5) 0 (0) 6 (6.4) 0 (0) 1 (1.6) 5 (17.9) 0 (0)
Endometrioid
uterine








42 (65.6) 13 (46.4) 4 (80)
Clear cell ovarian 7 (10.0) 4 (14.8) 9 (25) 2 (3.3) 6 (12.5) 5 (10.2) 11
(11.5)
0 (0) 6 (9.4) 5 (17.9) 0 (0)
Endometrioid
ovarian






0 (0) 15 (23.4) 5 (17.9) 1 (20)
P-value < 0.001 < 0.001 0.008 0.008 0.049 0.049 0.756 0.756 0.07 0.07 0.07
https://doi.org/10.1371/journal.pone.0192881.t002
Fig 2. Survival analysis for ARID1A. Survival was better for the subgroup of patients with ARID1A positive tumors (N = 27) compared to the subgroup with
ARID1A negative tumors (N = 70).
https://doi.org/10.1371/journal.pone.0192881.g002
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p53. p53 overexpression or complete absence was seen in 36 (37.1) out of 97 carcinoma.
The status of p53 was significantly (p = 0.008) associated with histological subtype (Table 2).
p53 overexpression or complete absence was seen mostly in clear cell tumors, but infrequent in
endometrioid carcinoma. The p53 status was not related to age (p = 0.487) or FIGO stage
(p = 0.081), but it was associated significantly (p< 0.001) with tumor grade. Overexpression or
no expression of p53 was most frequently seen in poorly differentiated (G3) clear cell and endo-
metrioid tumors and infrequent in G1 and G2 endometrioid tumors (S1 Table). Survival analy-
sis (Fig 3) showed significant (p = 0.003) differences for patients according to p53 status.
Patients with overexpression or complete absence of p53 in their tumors had a 5-year survival
rate of 51.5% compared to 76.5% survival for those with positive p53 expression. Significantly
better survival in the subgroup of p53 regulated tumors could also be observed for sole analysis
of all clear cell (p = 0.020) and all uterine carcinoma (p = 0.012) as well as tumors of grading G1
and G2 (p = 0.036) and G3 (p = 0.011) and tumors with FIGO staging 0, I and II (p = 0.012).
Fig 3. Survival analysis for p53. Survival was better for the subgroup of patients with p53 positive tumors (N = 61) compared to the subgroup with p53 negative/
overexpression tumors (N = 36).
https://doi.org/10.1371/journal.pone.0192881.g003
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p16. p16 overexpression or complete absence was seen in 48 (49.5) out of 97 tumors. The
p16 status was significantly (p = 0.049) related to histological subtype (Table 2). p16 overex-
pression or no expression was seen more frequently in clear cell tumors and it was infrequent
in endometrioid carcinoma. The p16 status alone was not associated with tumor grade
(p = 0.749), age (p = 0.359), FIGO stage (p = 0.645) or survival (p = 0.436).
p21. p21 nuclear positive staining was confined to the nucleus and observed in 3 (5.1%)
out of 97 carcinoma, which were all endometrioid uterine tumors. The p21 status was not
related to histological subtype (p = 0.756), grading (p = 0.114), age (p = 0.673), FIGO stage
(p = 0.433) or survival (p = 0.153).
ß-Catenin. ß-Catenin nuclear negative and positive membrane staining (n-m+) was
observed in 64 (66.0), ß-Catenin nuclear and membrane negative (n-m-) staining in 28 (28.8)
and ß-Catenin positive nuclear and membrane/cytoplasm staining (n+m+) in 5 (5.2) out of
97 tumors. The ß-Catenin status was significantly (p = 0.07) related to histological subtype
(Table 2). ß-Catenin n-m+ staining was more frequently seen in endometrioid tumors and it
was infrequent in clear cell carcinoma. ß-Catenin n+m+ staining was only observed in endo-
metrioid tumors, mostly in endometrial cancer. The ß-Catenin status was not related to age
(p = 0.483) or FIGO stage (p = 0.750). It was significantly (p = 0.046) associated with tumor
grade. Thus ß-Catenin n+m+ staining and n-m- staining was mostly seen in G2 and G3
tumors whereas positive membrane staining alone was almost evenly spread among all grad-
ing. Survival analysis (Fig 4) demonstrated significant (p = 0.028) differences for patients
according to ß-Catenin status.
Patients with n-m- staining for ß-Catenin in their tumors had a 5-year survival rate of
44.4% and patients with n+m+ staining had a 5-year survival rate of 40,0% compared to 78.5%
survival for those with n-m+ expression. Significantly better survival in the subgroup of
ß-Catenin n-m+ stained tumors could also be observed for sole analysis of all endometrioid
tumors (p = 0.031) and uterine carcinoma (p = 0.014) as well as tumors of grading G3 (p =
0.036) and tumors with FIGO staging III and IV (p = 0.021).
Relationship between ARID1A/ß-Catenin status, and ß-Catenin/p16 status
and their association to clinico-pathological data
Correlation between the expressions of the five different proteins was tested by using Pearsons
chi-square test (Table 3). A low significant correlation was found between ARID1A and ß-
Catenin with a corrected coefficient of contingency of Ccor = 0.282 (p = 0.045) and ß-Catenin
and p16 with a corrected coefficient of contingency of Ccor = 0.282 (p = 0.045). Further the dif-
ferences between the expressions of ARID1A/ß-Catenin and ß-Catenin/p16 were investigated
based on different clinical parameters, including age, histological subtype, grading and FIGO
staging. While the ARID1A/ß-Catenin status was not significantly related to age (p = 0.697), a
significant correlation to histological subtype (p< 0.001), grading (p = 0.018) and FIGO stag-
ing (p = 0.014) was observed (Table 4). ARID1A negative staining and simultaneous ß-Catenin
n+m+ staining was only seen in endometrioid uterine tumors. ARID1A negative staining and
simultaneous ß-Catenin n-m- staining was also observed mostly in endometrioid endometrial
cancer. This staining combination was found to be mostly in tumors with grading G3 and
FIGO staging IV. ARID1A positive staining and simultaneous ß-Catenin n-m+ staining were
mostly seen in endometrioid ovarian carcinoma and the tumors belonged mostly to FIGO
staging I.
The ß-Catenin/p16-status showed no significant correlation to the parameters mentioned
above (age (p = 0.750), histological subtype (p = 0.189), grading (p = 0.379) and FIGO staging
(p = 0.613)).
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Fig 4. Survival analysis for ß-Catenin. Survival analysis for ß-Catenin. Survival was better for the subgroup of patients with ß-Catenin n-m+ tumors (N = 64)
compared to the subgroup ß-Catenin n-m- (N = 28) and ß-Catenin n+m+ tumors (N = 5).
https://doi.org/10.1371/journal.pone.0192881.g004
Table 3. Correlation among ARID1A/ß-Catenin and ß-Catenin/p16 in endometrioid and clear cell ovarian and
uterine tissues.
ß-Catenin n-m-/n+m+ ß-Catenin n-m+
N (%) 33 (34.0) 64 (66.0) N (%)
ARID1A - 28 42 70 (72.2)
ARID1A + 5 22 27 (27.8)
Ccorr = 0.282, p-value: 0.045 97
P16 –o +++ 21 27 48 (49.5)
P16 + 12 37 49 (50.5)
Ccorr = 0.282, p-value: 0.045 97
Ccorr, corrected coefficient of contingency
https://doi.org/10.1371/journal.pone.0192881.t003
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Multivariate analysis
In a multivariate Cox regression analysis with tumor-related death as the end point signifi-
cant and independent prognostic factors were ARID1A status with hazard ratio (HR) of
3.359, p53 status with HR of 3.408, ß-Catenin status with HR of 2.251 and ARID1A/ß-Cate-
nin status with HR of 2.209 (Tables 5–8). An HR of 2.209 for concomitant ARID1A negativ-
ity and ß-Catenin n-m-/n+m+ staining of tumors versus other combinations of ARID1A/ß-
Catenin meant a 2.209 fold increased risk for tumor-related death for patients who belonged
to the first subgroup. Similarly, an HR of 3.359 for ARID1A negative tumors versus ARID1A
positive tumors, an HR of 3.408 for p53 aberrant expression versus p53 regulated expression
and an HR of 2.251 for ß-Catenin weak/negative membranous and positive nuclear expres-
sion versus ß-Catenin positive membranous expression meant a 3.359, 3.408 respectively
2.251 fold increased risk for tumor-related death for patients who belonged to the first
subgroups.
Table 4. Status of ARID1A/ß-Catenin according to histological subtype, grading and FIGO staging.















25 (25.8) 2 (2.1) 25 (25.8) 42 (43.3) 3 (3.1)
Histological subtype
Clear cell uterine 0 (0) 0 (0) 5 (20) 1 (2.4) 0 (0)
Endometrioid uterine 5 (20) 1 (50) 13 (52) 37 (88.1) 3 (100)
Clear cell ovarian 4 (16) 0 (0) 5 (20) 2 (4.8) 0 (0)
Endometrioid ovarian 16 (64) 1 (50) 2 (8) 2 (4.8) 0 (0)
P-value < 0.001
Grading
G1 7 (28) 1 (50) 3 (12) 16 (38.1) 0 (0)
G2 5 (20) 1 (50) 6 (24) 16 (38.1) 1 (33.3)
G3 13 (52) 0 (0) 16 (64) 10 (23.8) 2 (67.7)
P-value = 0.018
FIGO staging
FIGO I 13 (52) 1 (50) 4 (16) 6 (14.3) 0 (0)
FIGO II 6 (24) 1 (50) 4 (16) 9 (21.4) 0 (0)
FIGO III 4 (16) 0 (0) 7 (28) 12 (28.6) 1 (33.3)
FIGO IV 2 (8) 0 (0) 10 (40) 15 (35.7) 2 (67.7)
P-value = 0.014
https://doi.org/10.1371/journal.pone.0192881.t004
Table 5. Multivariate Cox regression analysis with tumor related death as endpoint for ARID1A.
Variable Hazard Ratio 95% Confidence Interval P-Value n
Age (years) 0.990 0.959–1.021 0.514 97
Histological subtype (endometrioid vs. clear cell carcinoma) 2.110 0.942–4.728 0.070 97
Grading
(G1+G2 vs. G3 tumors)
1.064 0.524–2.162 0.864 97
FIGO stage
(I+II vs. III + IV
tumors)
1.079 0.533–2.186 0.833 97
ARID1A (+ vs. -) 3.359 1.152–9.792 0.026 97
https://doi.org/10.1371/journal.pone.0192881.t005
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Discussion
Endometrial cancer can be subdivided into two histological subtypes, the estrogen-associated
type I which includes endometrioid carcinomas and the estrogen-independent type II which
comprises mostly high-grade serous and clear cell carcinoma [1]. The type II carcinoma is
known to metastasize more often and to have a worse survival. A less accepted paradigm for
ovarian cancer also differs between type I tumors which include endometrioid, clear cell and
low-grade serous carcinoma and type II tumors containing p53-mutated high-grade serous
carcinoma [2].
Many biomarkers, including different tumor suppressors such as ARID1A, p53, p21, p16
and ß-Catenin, were discovered to be changed in expression in endometrioid and clear cell
subtypes in recent years [26–29]. The aim of this study was to evaluate their prognostic value,
particularly in the synopsis of all the above mentioned factors, by using immunhistochemical
methods.
Ovarian clear cell carcinoma usually showed p53 overexpression or no expression (81.8%),
while ovarian endometrioid carcinoma mostly was observed to have positive p53 expression
(71.4%). Both subtypes consisted in equal parts of p16 overexpression/no expression or posi-
tive expression and all stained negatively for p21. These findings confirm the results of various
studies [30–32], which indicate that most of the ovarian clear cell tumors show p53 mutations,
while most of endometrioid tumors do not. There are several studies showing that p16 is over-
expressed in high-grade serous ovarian carcinoma compared with other morphologic types of
ovarian cancer [33], whereas inactivation of the gene was observed in 3 out of 9 endometrioid
and 1 out of 4 clear cell ovarian carcinomas [34]. Another study explored the expression of p21
in endometrioid and clear cell ovarian carcinoma and found p21 negativity in 59.5% (endome-
trioid) and 31.2% (clear cell) [35].
For endometrial carcinoma we can report that clear cell subtypes consisted in equal parts of
p53 overexpression/no expression or positive expression and all showed p16 overexpression/
Table 6. Multivariate Cox regression analysis with tumor related death as endpoint for p53.
Variable Hazard Ratio 95% Confidence Interval P-Value n
Age (years) 0.987 0.956–1.019 0.426 97
Histological subtype (endometrioid vs. clear cell carcinoma) 1.605 0.716–3.599 0.251 97
Grading
(G1+G2 vs. G3 tumors)
1.957 0.903–4.239 0.194 97
FIGO stage
(I+II vs. III + IV
tumors)
1.589 0.790–3.196 0.194 97
p53 (+ vs.—o+++) 3.408 1.567–7.415 0.002 97
https://doi.org/10.1371/journal.pone.0192881.t006
Table 7. Multivariate Cox regression analysis with tumor related death as endpoint for ß-Catenin.
Variable Hazard Ratio 95% Confidence Interval P-Value n
Age (years) 0.993 0.961–1.026 0.674 97
Histological subtype (endometrioid vs. clear cell carcinoma) 1.743 0.774–3.928 0.180 97
Grading
(G1+G2 vs. G3 tumors)
1.430 0.691–2.957 0.335 97
FIGO stage
(I+II vs. III + IV
tumors)
1.249 0.633–2.511 0.532 97
ß-Catenin
(n-m+ vs. n-m-/n+m+)
2.251 1.096–4.625 0.027 97
https://doi.org/10.1371/journal.pone.0192881.t007
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no expression while endometrioid subtypes mostly were found to have positive p53 (69.5%)
and p16 (69.4%) staining. Both subtypes were stained mostly p21 negative. In several studies,
the p53 mutation prevalence among clear cell uterine carcinoma ranges from 28.5% to 76.9%
[36,37].
For endometrioid uterine carcinoma however, most of the tumors appear to have no p53
mutation [38], which is in agreement with our results. In endometrioid uterine carcinoma the
expression pattern of p16 is typically described as weakly positive unlike the strong expression
generally seen in endocervial adenocarcinomas of the usual type [39]. However, another study
found up to 33% overexpression and 65% no expression in clear cell endometrial carcinoma
and different p16 expression in endometrioid endometrial carcinoma according to FIGO
grade [40]. In FIGO grade 1 and 2 endometrioid subtypes were found to be mostly stained p16
negative while in FIGO grade 3 about 25% turned out to be p16 positive. For p21 expression in
endometrial cancer some studies showed about 54% p21 negativity, increasing with older age
and current smoking [41]. In contrast to these results other studies figured out that p21 seems
to be mostly positively expressed in endometrial cancer [26]. The contradictory findings
related to p16 and p21 may be due to different staining protocols, cut-off values for p16 and
p21 expression, and characteristics of the study populations examined.
In this analysis the ß-Catenin expression of ovarian and uterine tumors was determined. ß-
Catenin mutations are particularly common in endometrioid ovarian and uterine cancer [22].
However, their prevalence ranges widely from 16–54% across the several studies [42]. It could
be confirmed that ß-Catenin n+m+ staining was only seen in endometrioid tumors, mostly
uterine.
ARID1A has been recently classified as a novel tumor suppressor, which regulates p53-con-
trolled genes [43]. Reduced ARID1A expression is mostly induced by nonsense mutations as
well as insertions and deletions in the gene-coding region, which lead to mRNA decay or
sequence truncation [44]. It has been published that promoter hypermethylation may also be
responsible for the loss of ARID1A expression [45]. ARID1A mutations are frequently in vari-
ous tumors including gastric cancer, colorectal cancer, breast cancer, lung cancer and gynaeco-
logical cancer [46]. High rates of ARID1A mutations were observed in 46–57% of ovarian
clear cell carcinomas, 30% of ovarian endometrioid carcinomas and 40% of uterine endome-
trioid carcinomas [15,47,48]. In this study, we also demonstrated that negative expression of
ARID1A was common in clear cell (63.6%) and endometrioid (19%) ovarian tumors as well
as clear cell (100%) and endometrioid (89.8%) uterine cancer. Moreover, we determined a sig-
nificant relationship between ARID1A loss and higher FIGO stages which is similar to previ-
ous studies [49,50].
No study could be found that examined the combined ARD1A/ß-Catenin status of ovarian
and uterine tumors yet. However, few studies indicate that there is an association between
Table 8. Multivariate Cox regression analysis with tumor related death as endpoint for ARID1A/ß-Catenin status.
Variable Hazard Ratio 95% Confidence Interval P-Value n
Age (years) 0.992 0.960–1.024 0.614 97
Histological subtype (endometrioid vs. clear cell carcinoma) 1.678 0.736–3.822 0.218 97
Grading
(G1+G2 vs. G3 tumors)
1.459 0.696–3.058 0.317 97
FIGO stage
(I+II vs. III + IV
tumors)
1.198 0.593–2.421 0.614 97
Others vs. ARID1A-/ß-Catenin n-m-/ß-Catenin n+m+ 2.209 1.031–4.734 0.041 97
https://doi.org/10.1371/journal.pone.0192881.t008
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the two tumor suppressor genes. ARID1A silencing seems to be inducing a subcellular redistri-
bution of β-catenin from the plasma membrane to the cytoplasm and nucleus in gastric cancer,
which was found to be significantly associated with worse clinical prognosis [51]. Another
study demonstrated that the chromatin-remodeling factor ARID1B, forming the BAF complex
together with ARID1A, represses the Wnt/ß-Catenin signaling pathway indicating this might
contribute to cancer through deregulation of developmental and oncogenic pathways [52]. It
also suggests ARID1A might operate in a similar fashion as ARID1B in Wnt/β-Catenin path-
way. In this study a significant correlation between ARID1A and ß-Catenin could be shown.
Concomitantly ARID1A negative staining and ß-Catenin n+m+ staining respectively ß-Cate-
nin n-m- staining was usually seen in endometrioid uterine cancer with poor grading (G2 and
G3) and poor FIGO staging (FIGO III and FIGO IV). In a multivariate Cox Regression analy-
sis this staining combination of ARID1A and ß-Catenin meant a 2.209 fold increased risk for
tumor-related death. This indicates that the ARID1A/ß-Catenin pathway connection might
play a role in tumor progression in endometrioid endometrial carcinoma. It could already be
demonstrated that ARID1A loss and ß-Catenin mutation, each seen individually, are impor-
tant in progression of different types of human cancer [16,53,54]. Additional studies will have
to be conducted to evaluate the association between ß-Catenin and the chromatin remodelling
gene ARID1A in uterine endometrioid carcinoma further.
In the present study it was possible to identify three prognostic factors that showed differ-
ences in independent survival analysis. For the tumor suppressor gene p53 we were able to
show that patients with overexpression or no expression of p53 had a worse overall survival
compared to those with normal p53 expression. This is consistent with a number of studies
determining the prognostic value of p53 in ovarian and uterine carcinoma [27,35] and in con-
trast to other studies [54,55].
It could be observed that nuclear and membrane/cytoplasm positive staining as well as
nuclear and membrane negative staining of ß-Catenin were markers for worse overall survival
which agrees with some studies [56,57] that show reduced ß-Catenin cell surface expression
was a predictor for poor survival but not with other studies [58,59] that associate strong mem-
branous β-Catenin expression with shorter progression free survival. Discordance between
these results could be due to different patterns of ß-Catenin and p53 expression in ovarian and
uterine carcinoma, especially in different staging and grading, and differences in the methods
of immunohistochemical interpretation.
Similar to previous studies it could be determined that ARID1A loss in ovarian and uterine
tumors is a predictor for poor survival [49,60–62]. ARID1A expression was also reported to be
a prognostic marker for several other cancers such as gastric cancer, clear cell renal cell carci-
noma and cervical cancer [63–65].
At this point some limitations of this study may be noted which can be addressed in future
studies. They include mostly the limited numbers of cases within histological subgroups, espe-
cially clear cell carcinoma with a total number of only 17 cases. To prevent the effect, that ovar-
ian and uterine carcinoma can be very heterogeneous in immunohistochemical interpretation
the tissue microarray construction was done by using three core biopsies from each specimen.
Nevertheless some cases might not have been adequately represented due to loss of cancer tis-
sue material.
In summary, a significant association between AIRD1A and ß-Catenin expression was dis-
covered in endometrioid uterine tumors. This suggests that concomitantly ARID1A negative
staining and ß-Catenin nuclear and membrane/cytoplasm positive (n+m+) staining respec-
tively ß-Catenin nuclear and membrane negative staining (n-m-) might play a role in tumor
progression in type I endometrial cancer. Furthermore ARID1A, p53 and ß-Catenin turned
out to be three promising prognostic factors showing significant differences in independent
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survival analysis, indicating that ARID1A, p53 and ß-Catenin could be used along traditional
clinical and morphologic factors to predict the prognosis of patients with clear cell and endo-
metrioid ovarian and uterine cancer.
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